Skip to main content
SpringerLink
Log in

Racial Disparities in the Treatment of Schizophrenia Spectrum Disorders: How Far Have We Come?

  • Psychosis (A Ahmed, Section Editor)
  • Published:
Current Behavioral Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This paper reviews the literature examining antipsychotic prescription disparities between white people and black people.

Recent Findings

Despite literature documenting racial discrepancies in diagnosis, there have been limited studies examining disparities in antipsychotic prescription between white people and black people. Studies have demonstrated that black people are more likely to receive first generation antipsychotics, higher antipsychotic doses, and long acting injectables, but less likely to receive clozapine. Much of this work was done in the early 2000s.

Summary

Future research directions include investigation into why these disparities exist. Literature examining these disparities has focused on genetic and sociological factors; however, the impact of prescriber bias and structural racism remains underexplored. Until the research proceeds, future clinical directions should include empowering patients, families, and clinicians to question practices that may exacerbate these known disparities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. https://doi.org/10.1093/schbul/sbp116.

    Article  PubMed  Google Scholar 

  2. Strakowski SM, Shelton RC, Kolbrener ML. The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry. 1993;54(3):96–102.

    CAS  PubMed  Google Scholar 

  3. Strakowski SM, Lonczak HS, Sax KW, West SA, Crist A, Mehta R, Thienhaus OJ. The effects of race on diagnosis and disposition from a psychiatric emergency service. J Clin Psychiatry. 1995;56(3):101–7.

    CAS  PubMed  Google Scholar 

  4. Chinman MJ, Rosenheck RA, Lam JA. Client-case manager racial matching in a program for homeless persons with serious mental illness. Psychiatr Serv. 2000;51(10):1265–72. https://doi.org/10.1176/appi.ps.51.10.1265.

    Article  CAS  PubMed  Google Scholar 

  5. DelBello MP, Lopez-Larson MP, Soutullo CA, Strakowski SM. Effects of race on psychiatric diagnosis of hospitalized adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2001;11(1):95–103. https://doi.org/10.1089/104454601750143528.

    Article  CAS  PubMed  Google Scholar 

  6. Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, Russo PA. A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. Schizophr Res. 2003;60(2–3):259–69. https://doi.org/10.1016/s0920-9964(02)00223-2.

    Article  PubMed  Google Scholar 

  7. Barnes A. Race, schizophrenia, and admission to state psychiatric hospitals. Adm Policy Ment Health. 2004;31(3):241–52. https://doi.org/10.1023/b:apih.0000018832.73673.54.

    Article  PubMed  Google Scholar 

  8. Bresnahan M, Begg MD, Brown A, Schaefer C, Sohler N, Insel B, Vella L, Susser E. Race and risk of schizophrenia in a US birth cohort: another example of health disparity? Int J Epidemiol. 2007;36(4):751–8. https://doi.org/10.1093/ije/dym041.

    Article  PubMed  Google Scholar 

  9. Barnes A. Race and hospital diagnoses of schizophrenia and mood disorders. Soc Work. 2008;53(1):77–83. https://doi.org/10.1093/sw/53.1.77.

    Article  PubMed  Google Scholar 

  10. Anglin DM, Malaspina D. Racial and ethnic effects on psychotic psychiatric diagnostic changes from admission to discharge: a retrospective chart review. J Clin Psychiatry. 2008;69(3):464–9. https://doi.org/10.4088/jcp.v69n0318.

    Article  PubMed  Google Scholar 

  11. Gara MA, Vega WA, Arndt S, Escamilla M, Fleck DE, Lawson WB, Lesser I, Neighbors HW, Wilson DR, Arnold LM, Strakowski SM. Influence of patient race and ethnicity on clinical assessment in patients with affective disorders. Arch Gen Psychiatry. 2012;69(6):593–600. https://doi.org/10.1001/archgenpsychiatry.2011.2040.

    Article  PubMed  Google Scholar 

  12. Durbin A, Rudoler D, Durbin J, Laporte A, Callaghan RC. Examining patient race and area predictors of inpatient admission for schizophrenia among hospital users in California. J Immigr Minor Health. 2014;16(6):1025–34. https://doi.org/10.1007/s10903-013-9831-7.

    Article  PubMed  Google Scholar 

  13. Schwartz RC, Blankenship DM. Racial disparities in psychotic disorder diagnosis: a review of empirical literature. World J Psychiatry. 2014;4:133–40. https://doi.org/10.5498/wjp.v4.i4.133.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Coleman KJ, Stewart C, Waitzfelder BE, Zeber JE, Morales LS, Ahmed AT, Ahmedani BK, Beck A, Copeland LA, Cummings JR, Hunkeler EM, Lindberg NM, Lynch F, Lu CY, Owen-Smith AA, Trinacty CM, Whitebird RR, Simon GE. Racial-ethnic differences in psychiatric diagnoses and treatment across 11 health care systems in the mental health research network. Psychiatr Serv. 2016;67(7):749–57. https://doi.org/10.1176/appi.ps.201500217.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Maura J, de Weisman MA. Mental health disparities, treatment engagement, and attrition among racial/ethnic minorities with severe mental illness: a review. J Clin Psychol Med Settings. 2017;24(34):187–210. https://doi.org/10.1007/s10880-017-9510-2.

    Article  PubMed  Google Scholar 

  16. Olbert CM, Nagendra A, Buck B. Meta-analysis of Black vs. White racial disparity in schizophrenia diagnosis in the United States: do structured assessments attenuate racial disparities? J Abnorm Psychol. 2018;127(1):104–15. https://doi.org/10.1037/abn0000309.

    Article  PubMed  Google Scholar 

  17. Gara MA, Minsky S, Silverstein SM, Miskimen T, Strakowski SM. A Naturalistic study of racial disparities in diagnoses at an outpatient behavioral health clinic. Psychiatr Serv. 2019;70(2):130–4. https://doi.org/10.1176/appi.ps.201800223.

    Article  PubMed  Google Scholar 

  18. Wiener HW, Klei L, Irvin MD, Perry RT, Aliyu MH, Allen TB, Bradford LD, Calkins ME, Devlin B, Edwards N, Gur RE, Gur RC, Kwentus J, Lyons PD, McEvoy JP, Nasrallah HA, Nimgaonkar VL, O’Jile J, Santos AB, Savage RM, Go RC. Linkage analysis of schizophrenia in African-American families. Schizophr Res. 2009;109(1–3):70–9. https://doi.org/10.1016/j.schres.2009.02.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. •• Eack SM, Bahorik AL, Newhill CE, Neighbors HW, Davis LE. Interviewer-perceived honesty as a mediator of racial disparities in the diagnosis of schizophrenia. Psychiatr Serv. 2012;63(9):875–80. https://doi.org/10.1176/appi.ps.201100388. (This paper suggests that clinician perception of the patient strongly influences diagnosis, demonstrating that disparities in schizophrenia diagnosis are influenced by the interviewer’s perception that the patient is not honest during the interview, which appears to occur more frequently in African American patients.)

    Article  PubMed  PubMed Central  Google Scholar 

  20. Davidson JR, Raft D, Lewis BF, Gebhardt M. Psychotropic drugs on general medical and surgical wards of a teaching hospital. Arch Gen Psychiatry. 1975;32(4):507–11. https://doi.org/10.1001/archpsyc.1975.01760220119012.

    Article  CAS  PubMed  Google Scholar 

  21. Rossiter LF. Prescribed medicines: findings from the National Medical Care Expenditure Survey. Am J Public Health. 1983;73(11):1312–5. https://doi.org/10.2105/ajph.73.11.1312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. •• Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159(4):567–72. https://doi.org/10.1176/appi.ajp.159.4.567. (This study is one of the largest in this area, published nearly twenty years ago, examining Medicaid claims records from over 2500 people in 1995)

    Article  PubMed  Google Scholar 

  23. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17–29. https://doi.org/10.1093/oxfordjournals.schbul.a006920.

    Article  PubMed  Google Scholar 

  24. •• Copeland LA, Zeber JE, Valenstein M, Blow FC. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003;160(10):1817–22. https://doi.org/10.1176/appi.ajp.160.10.1817. (This paper examined prescribing practices among patients receiving care through the Department of Veterans Affairs in 1999, including nearly 70,000 records in their analysis. The authors demonstrated prescribing disparities in both African American and Latino populations)

    Article  PubMed  Google Scholar 

  25. •• Daumit GL, Crum RM, Guallar E, Powe NR, Primm AB, Steinwachs DM, Ford DE. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003;60(2):121–8. https://doi.org/10.1001/archpsyc.60.2.121. (This paper demonstrated that black people were about half as likely to receive second generation antipsychotics vs first generation antipsychotics compared to white people in a sample of approximately 5000 people over 1992–2000. They examined how the trend changed over time, and while the gap did decrease with each two year period, black people were still less likely to be prescribed second generation antipsychotics in 1998–2000)

    Article  PubMed  Google Scholar 

  26. Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MT, Gibson PJ. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. J Clin Psychiatry. 2003;64(6):635–9. https://doi.org/10.4088/jcp.v64n0603.

    Article  PubMed  Google Scholar 

  27. Valenti AM, Narendran R, Pristach CA. Who are patients on conventional antipsychotics? Schizophr Bull. 2003;29(2):195–9. https://doi.org/10.1093/oxfordjournals.schbul.a006997.

    Article  PubMed  Google Scholar 

  28. •• Kreyenbuhl J, Zito JM, Buchanan RW, Soeken KL, Lehman AF. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;2:183–93. https://doi.org/10.1093/oxfordjournals.schbul.a006996. (This study used a medical record review of patients recruited from the Patient Outcomes Research Team (PORT) study in a part of the study aimed at understanding variations in treatment among people with schizophrenia)

    Article  Google Scholar 

  29. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004;55(2):151–6. https://doi.org/10.1176/appi.ps.55.2.151.

    Article  PubMed  Google Scholar 

  30. •• Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, Snowden LR. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv. 2004;55(6):677–84. https://doi.org/10.1176/appi.ps.55.6.677. (The authors suggest that increase prescription of first generation antipsychotics among African Americans leads to an increase in side effects and, in turn, and increase in nonadherence)

    Article  PubMed  Google Scholar 

  31. Puyat JH, Daw JR, Cunningham CM, Law MR, Wong ST, Greyson DL, Morgan SG. Racial and ethnic disparities in the use of antipsychotic medication: a systematic review and meta-analysis. Soc Psychiatry Psychiatr Epidemiol. 2013;48(12):1861–72. https://doi.org/10.1007/s00127-013-0753-4.

    Article  PubMed  Google Scholar 

  32. Cook TB, Reeves GM, Teufel J, Postolache TT. Persistence of racial disparities in prescription of first-generation antipsychotics in the USA. Pharmacoepidemiol Drug Saf. 2015;24(11):1197–206. https://doi.org/10.1002/pds.3819.

    Article  CAS  PubMed  Google Scholar 

  33. Pan I (2016) Association between race/ethnicity and the receipt of outpatient second-generation antipsychotic agents stratified by metabolic effects. Thesis Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of Master of Science in Pharmaceutical Sciences. The University of Texas at Austin August

  34. Lawson W, Johnston S, Karson C, Offord S, Docherty J, Eramo A, Kamat S, Blanchette CM, Carson W, Nasrallah HA. Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry. 2015;27(4):242–52.

    PubMed  Google Scholar 

  35. De Leon J, Diaz F, Josiassen R, Cooper T, Simpson G. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007;27(1):22–7. https://doi.org/10.1097/JCP.0b013e31802e513a.

    Article  CAS  PubMed  Google Scholar 

  36. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1–3):95–102. https://doi.org/10.1016/j.schres.2009.02.006.

    Article  PubMed  Google Scholar 

  37. Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol. 2013;3(1):33–51. https://doi.org/10.1177/2045125312464385.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hwang R, Shinkai T, De Luca V, Müller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005;181(1):179–87. https://doi.org/10.1007/s00213-005-2223-5.

    Article  CAS  PubMed  Google Scholar 

  39. •• Price N, Glazer W, Morgenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry. 1985;142(12):1491–2. https://doi.org/10.1176/ajp.142.12.1491. (Evidence of disparities in long acting injectable use were published as early as 1985, before second-generation antipsychotics came to market)

    Article  CAS  PubMed  Google Scholar 

  40. Chen EY, Harrison G, Standen PJ. Management of first episode psychotic illness in Afro-Caribbean patients. Br J Psychiatry. 1991;158:517–22. https://doi.org/10.1192/bjp.158.4.517.

    Article  CAS  PubMed  Google Scholar 

  41. Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry. 1994;45(1):38–42. https://doi.org/10.1176/ps.45.1.38.

    Article  CAS  PubMed  Google Scholar 

  42. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull. 1996;32(3):321–6.

    CAS  PubMed  Google Scholar 

  43. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007;58(4):482–8. https://doi.org/10.1176/ps.2007.58.4.482.

    Article  PubMed  Google Scholar 

  44. Brown JD, Barrett A, Caffery E, Hourihan K, Ireys HT. State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia. Psychiatr Serv. 2014;65(1):121–4. https://doi.org/10.1176/appi.ps.201300001.

    Article  PubMed  Google Scholar 

  45. Kishimoto T, Sanghani S, Russ MJ, Marsh AN, Morris J, Basu S, John M, Kane JM. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting. Int Clin Psychopharmacol. 2017;32(3):161–8. https://doi.org/10.1097/YIC.0000000000000165.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Diaz E, Woods SW, Rosenheck RA. Effects of ethnicity on psychotropic medications adherence. Community Ment Health J. 2005;41(5):521–37. https://doi.org/10.1007/s10597-005-6359-x.

    Article  PubMed  Google Scholar 

  47. •• Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255–64. https://doi.org/10.1093/oxfordjournals.schbul.a007076. (Using medical records from over 60,000 patients receiving care at the Department of Veterans Affairs, the authors conclude that young, African American people and people taking first generation antipsychotics are most likely to be non-adherent. While a change from a first-generation to second-generation antipsychotic does improve adherence, the improvement was not robust enough to fully explain the disparity)

    Article  PubMed  Google Scholar 

  48. Mark TL, Palmer LA, Russo PA, Vasey J. Examination of treatment pattern differences by race. Ment Health Serv Res. 2003;4:241–50. https://doi.org/10.1023/a:1026281118990.

    Article  Google Scholar 

  49. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry. 2000;61(5):382–6.

    Article  CAS  Google Scholar 

  50. Sellwood W, Tarrier N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1994;29(4):172–7. https://doi.org/10.1007/BF00802014.

    Article  CAS  PubMed  Google Scholar 

  51. Boulware LE, Cooper LA, Ratner LE, LaVeist TA, Powe NR. Race and trust in the health care system. Public Health Rep. 2003;118(4):358–65. https://doi.org/10.1093/phr/118.4.358.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Armstrong K, Ravenell KL, McMurphy S, Putt M. Racial/ethnic differences in physician distrust in the United States. Am J Public Health. 2007;97(7):1283–9. https://doi.org/10.2105/AJPH.2005.080762.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Clark PA. A legacy of mistrust: African-Americans, the medical profession, and AIDS. Linacre Q. 1998;65(1):66–88. https://doi.org/10.1080/00243639.1998.11878407.

    Article  PubMed  Google Scholar 

  54. Gamble VN. Under the shadow of Tuskegee: African Americans and health care. Am J Public Health. 1997;87(11):1773–8. https://doi.org/10.2105/ajph.87.11.1773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Young AS, Sullivan G, Duan N. Patient, provider, and treatment factors associated with poor-quality care for schizophrenia. Ment Health Serv Res. 1999;1(4):201–11. https://doi.org/10.1023/a:1022369323451.

    Article  CAS  PubMed  Google Scholar 

  56. Aggarwal NK, Rosenheck RA, Woods SW, Sernyak MJ. Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review. J Clin Psychiatry. 2012;73(4):513–7. https://doi.org/10.4088/JCP.11m07161.

    Article  PubMed  Google Scholar 

  57. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S63–7. https://doi.org/10.1192/bjp.195.52.s63.

    Article  PubMed  Google Scholar 

  58. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, WFSBP Task force on treatment guidelines for schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44. https://doi.org/10.3109/15622975.2012.739708.

    Article  PubMed  Google Scholar 

  59. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP, Expert consensus panel on adherence problems in serious and persistent mental illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46.

    Article  PubMed  Google Scholar 

  60. Kane JM, Zhao C, Johnson BR, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 2015;18:145–54.

    Article  Google Scholar 

  61. Taylor D, Olofinjana O. Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol. 2014;29:229–34.

    Article  Google Scholar 

  62. Kamat SA, Offord S, Docherty J, et al. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015;4:1–12. https://doi.org/10.7573/dic.212267.

    Article  Google Scholar 

  63. Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl. 2009;52:S37-42. https://doi.org/10.1192/bjp.195.52.s37.

    Article  PubMed  Google Scholar 

  64. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995–1001. https://doi.org/10.1093/schbul/sbm137.

    Article  PubMed  Google Scholar 

  65. Owen RR, Fischer EP, Kirchner JE, Thrush CR, Williams DK, Cuffel BJ, Elliott CE, Booth BM. Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. Am J Med Qual. 2003;18(4):140–6. https://doi.org/10.1177/106286060301800402.

    Article  PubMed  Google Scholar 

  66. Soleman M, Lam N, Woo BK. Ethnic and age disparities in patients taking long-acting injectable atypical antipsychotics. Cureus. 2017;9(10): e1772. https://doi.org/10.7759/cureus.1772.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Chung H, Mahler JC, Kakuma T. Racial differences in treatment of psychiatric inpatients. Psychiatr Serv. 1995;46(6):586–91. https://doi.org/10.1176/ps.46.6.586.

    Article  CAS  PubMed  Google Scholar 

  68. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1–10. https://doi.org/10.1093/oxfordjournals.schbul.a033302.

    Article  CAS  PubMed  Google Scholar 

  69. Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry. 2000;61(5):344–8. https://doi.org/10.4088/jcp.v61n0504.

    Article  CAS  PubMed  Google Scholar 

  70. •• Valenstein M, Copeland L, Owen R, Blow F, Visnic S. Delays in adopting evidence-based dosages of conventional antipsychotics. Psychiatr Serv. 2001;52(9):1242–4. https://doi.org/10.1176/appi.ps.52.9.1242. (The authors demonstrate that African American patients are more likely to receive high doses of antipsychotic medications, suggesting that providers are slower or less likely to adhere to evidence-based guidelines in treating African American patients)

    Article  CAS  PubMed  Google Scholar 

  71. dos Reis S, Zito JM, Buchanan RW, Lehman AF. Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia. Schizophr Bull. 2002;28(4):607–17. https://doi.org/10.1093/oxfordjournals.schbul.a006968.

    Article  Google Scholar 

  72. Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res. 2004;66(2–3):169–75. https://doi.org/10.1016/S0920-9964(03)00102-6.

    Article  PubMed  Google Scholar 

  73. Bakare MO. Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference? BMC Res Notes. 2008;1:25. https://doi.org/10.1186/1756-0500-1-25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Flaskerud JH, Hu LT. Racial/ethnic identity and amount and type of psychiatric treatment. Am J Psychiatry. 1992;149(3):379–84. https://doi.org/10.1176/ajp.149.3.379.

    Article  CAS  PubMed  Google Scholar 

  75. Dixon L, Lyles A, Smith C, Hoch JS, Fahey M, Postrado L, Lucksted A, Lehman A. Use and costs of ambulatory care services among Medicare enrollees with schizophrenia. Psychiatr Serv. 2001;52(6):786–92. https://doi.org/10.1176/appi.ps.52.6.786.

    Article  CAS  PubMed  Google Scholar 

  76. Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, Brown CH, Conley RR. Clozapine utilization and outcomes by race in a public mental health system: 1994–2000. J Clin Psychiatry. 2006;67(9):1404–11. https://doi.org/10.4088/jcp.v67n0911.

    Article  CAS  PubMed  Google Scholar 

  77. •• Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull. 2007;33(5):1221–4. https://doi.org/10.1093/schbul/sbl068. (In this study including 1875 people, more white people developed leucopenia and agranulocytosis of clozapine than black people. The authors advocated for reconsidering the prescribing guidelines to better recognize differences in white blood cell counts between black and white people, a change that ultimately occurred several years later)

    Article  PubMed  Google Scholar 

  78. Manuel JI, Essock SM, Wu Y, Pangilinan M, Stroup S. Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatr Serv. 2012;63(11):1146–9. https://doi.org/10.1176/appi.ps.201100435.

    Article  PubMed  Google Scholar 

  79. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2014;65(2):186–92. https://doi.org/10.1176/appi.ps.201300180.

    Article  PubMed  Google Scholar 

  80. •• Das-Munshi J, Bhugra D, Crawford MJ. Ethnic minority inequalities in access to treatments for schizophrenia and schizoaffective disorders: findings from a nationally representative cross-sectional study. BMC Med. 2018;16(1):55. https://doi.org/10.1186/s12916-018-1035-5. (This study was published after individuals with benign ethnic neutropenia were included as eligible to receive treatment with clozapine)

    Article  PubMed  PubMed Central  Google Scholar 

  81. •• Williams JC, Harowitz J, Glover J, Tek C, Srihari V. Systematic review of racial disparities in clozapine prescribing. Schizophr Res. 2020;224:11–8. https://doi.org/10.1016/j.schres.2020.07.023. (This 2020 review on racial disparities and clozapine prescription is the most extensive summary of the literature to date)

    Article  PubMed  Google Scholar 

  82. Manu P, Sarvaiya N, Rogozea LM, Kane JM, Correll CU. Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations. J Clin Psychiatry. 2016;77(7):e909–16. https://doi.org/10.4088/JCP.15r10085.

    Article  PubMed  Google Scholar 

  83. Richardson CM, Davis EA, Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia. J Clin Psychiatry. 2016;77(11):e1454–9. https://doi.org/10.4088/JCP.15m10315.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Program, C. R, 2016. Important program update (as of 12/16/2016). Clozapine REMS program. Retrieved July 10th 2018.

  85. Horvitz-Lennon M, Volya R, Donohue JM, Lave JR, Stein BD, Normand SL. Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002–2008. Health Serv Res. 2014;49(4):1121–44. https://doi.org/10.1111/1475-6773.12162.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Snowden LR, Cheung FK. Use of inpatient mental health services by members of ethnic minority groups. Am Psychol. 1990;45(3):347–55. https://doi.org/10.1037//0003-066x.45.3.347.

    Article  CAS  PubMed  Google Scholar 

  87. •• Horvitz-Lennon M, Donohue JM, Lave JR, Alegría M, Normand SL. The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries. Psychiatr Serv. 2013;64(3):230–7. https://doi.org/10.1176/appi.ps.201200041. (This study, which included over 20,000 people, demonstrates that the effectiveness of clozapine is similar across races and remains the most effective antipsychotic for treatment resistant schizophrenia)

    Article  PubMed  PubMed Central  Google Scholar 

  88. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull. 2003L;29(3):531–40.

    Article  Google Scholar 

  89. Velligan DI, Carroll C, Lage MJ, Fairman K. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatr Serv. 2015;66:127–33. https://doi.org/10.1176/appi.ps.201300085.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Westchester Behavioral Health Center, New York Presbyterian Hospital, 21 Bloomingdale Road, White Plains, NY, 10605, USA

    Emily Menand & Rachel Moster

Authors
  1. Emily Menand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Moster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel Moster.

Ethics declarations

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Menand, E., Moster, R. Racial Disparities in the Treatment of Schizophrenia Spectrum Disorders: How Far Have We Come?. Curr Behav Neurosci Rep 8, 179–186 (2021). https://doi.org/10.1007/s40473-021-00236-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40473-021-00236-7

Keywords

Search

Navigation